Here’s Why Investing in Cardinal Health Shares Could Benefit Your Portfolio Today

Cardinal Health: Positioned for Ongoing Expansion

Cardinal Health (CAH) is set for further advancement, driven by the broadening of its specialty offerings. The company reported impressive results for its fiscal second quarter, propelled by heightened demand in pharmaceutical distribution and rapid growth in specialty services. Continued progress in theranostics, home-based healthcare solutions, and logistics, along with a rebound in its medical division, are reinforcing Cardinal Health’s positive long-term profit outlook.

Over the last six months, this Zacks Rank #2 (Buy) stock has surged 49.2%, outpacing the medical services industry, which grew 23.3%, and the S&P 500’s 6.4% gain during the same period.

With a market value of $53.26 billion, Cardinal Health anticipates a 15% growth rate over the next five years and foresees ongoing operational improvements. The company has exceeded Zacks Consensus earnings estimates in each of the last four quarters, averaging a 9.3% positive surprise.

Image Source: Zacks Investment Research

Let’s take a closer look at the company’s strengths and challenges.

Key Strengths

Robust Growth in Pharmaceutical and Specialty Solutions

The Pharmaceutical and Specialty Solutions division saw notable gains, with revenue climbing 19% to $61 billion and segment profit up 29% in the second quarter of fiscal 2026. This growth was fueled by strong demand for branded, specialty, and generic drugs, as well as contributions from specialty distribution, MSO platforms, and biopharma services. Management expects specialty revenues to surpass $50 billion in fiscal 2026, highlighting the company’s successful shift toward higher-margin specialty therapies like oncology and urology. This strategic focus enhances Cardinal Health’s standing in the rapidly expanding specialty pharmaceutical market.

Diversification Through High-Growth Adjacent Businesses

Cardinal Health’s other growth areas—including Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics—achieved 34% revenue growth and a 52% increase in profits during the fiscal second quarter. These results were supported by industry trends such as the adoption of theranostics, the rise of home healthcare, and improvements in supply chain efficiency. Theranostics alone delivered over 30% revenue growth, backed by a pipeline of more than 70 products. These segments offer faster growth and higher margins than traditional distribution, enabling Cardinal Health (CAH) to broaden its income sources and reduce dependence on its lower-margin core business.

Turnaround in the Global Medical Products and Distribution Segment

The Global Medical Products and Distribution (GMPD) segment demonstrated significant progress, with profits rising from $18 million to $37 million year-over-year. This improvement is attributed to operational restructuring, cost-saving measures, and increased demand for Cardinal Health-branded products, which saw a 10% uptick in the U.S. Enhanced service levels and supply chain effectiveness, following investments in manufacturing and logistics, also contributed. If these operational improvements persist, GMPD could shift from being a drag on earnings to a positive contributor to profitability and margin growth.

Challenges Ahead

Expected Slowdown in Profit Growth

Despite a strong start to fiscal 2026, Cardinal Health anticipates that profit growth in its Pharma segment will slow to mid-teen percentages in the second half of the year. This moderation is due to challenging year-over-year comparisons, as the company onboarded $10 billion in new customers last year and is now cycling past previous acquisitions. While demand remains solid, the fading of these one-time growth drivers may dampen earnings momentum, suggesting that some recent gains were temporary rather than entirely organic.

Impact of Tariffs and Supply Chain Expenses

The GMPD segment continues to face external cost challenges, particularly from tariffs on medical product sourcing. Although cost-saving initiatives have offset some of these pressures, tariffs still negatively affected segment profitability this quarter. Given the global nature of medical product manufacturing, ongoing trade tensions or supply chain disruptions could further raise procurement costs, squeeze margins, and slow the pace of the GMPD turnaround.

Limited Margin Expansion in Core Distribution

Cardinal Health’s pharmaceutical distribution business, while sizable and stable, operates with inherently slim margins and relies on high volume. Management noted that major drug categories, such as GLP-1 therapies, significantly boost revenue but have minimal impact on profitability due to the business model’s economics. As a result, future earnings growth will increasingly depend on specialty services and adjacent businesses rather than the core distribution segment alone.

Trends in Analyst Estimates

Analyst sentiment for Cardinal Health’s 2026 outlook has improved. Over the past month, the Zacks Consensus Estimate for earnings per share (EPS) has risen by 2.7% to $10.31.

For the third quarter of fiscal 2026, the Zacks Consensus Estimate projects revenues of $62.42 billion, a 13.7% increase from the previous year. The EPS estimate stands at $2.80, representing a 19.2% year-over-year gain.

Cardinal Health, Inc. Stock Performance

Other Noteworthy Medical Stocks

Additional top-rated stocks in the medical sector include Globus Medical (GMED), Pacific Biosciences of California (PACB), and Edwards Lifesciences (EW).

• Globus Medical (Zacks Rank #1 - Strong Buy) posted fourth-quarter 2025 adjusted EPS of $1.28, exceeding expectations by 20.8%. Revenue reached $826 million, 4.9% above estimates. The company has a projected long-term earnings growth rate of 9.6%, compared to the industry’s 14%. Globus Medical has outperformed earnings estimates in each of the last four quarters, with an average surprise of 13.2%.
• Pacific Biosciences of California (Zacks Rank #1) reported a fourth-quarter 2025 adjusted loss per share of 12 cents, beating estimates by 36.8%. Revenue of $45 million surpassed expectations by 9.4%. The company is expected to see a 1.9% decline in earnings, compared to the industry’s 11.4% improvement, but has exceeded earnings estimates in each of the last four quarters, with an average surprise of 27.7%.
• Edwards Lifesciences (Zacks Rank #2 - Buy) announced second-quarter fiscal 2026 adjusted EPS of 58 cents, missing estimates by 6.5%, but revenue of $1.57 billion topped projections by 2%. The company’s estimated long-term earnings growth rate is 12.9%, just below the industry’s 14%. Edwards Lifesciences has beaten earnings estimates in three of the last four quarters, with an average surprise of 5.5%.

Quantum Computing: The Next Big Investment Opportunity

Artificial intelligence has already transformed investing, and its intersection with quantum computing could unlock unprecedented wealth-building potential.

Now is your chance to position your portfolio at the forefront of this technological revolution. Our special report, Beyond AI: The Quantum Leap in Computing Power, highlights lesser-known stocks that could lead the quantum computing race and deliver significant gains to early investors.